Click here for Analysts' Upgrades, Downgrades.

Editor's Note: Green and red arrows refer to intraday stock price movement.



) --


(ABC) - Get Report

added to Conviction Buy List at Goldman. Company has good earnings visibility over the next couple of years.


(AGCO) - Get Report

estimates, target upped at Goldman. AGCO estimates were boosted through 2012. Visibility is improving for demand in Western Europe. Buy rating and new $55 price target.

Allegiant Travel

(ALGT) - Get Report

price target cut at Barclays to $59 from $61. Investing in ALGT is risky, outlook uncertain, Barclays said. Maintain Overweight rating.

Applied Materials

(AMAT) - Get Report

target, estimates higher at Credit Suisse. AMAT price target raised by a dollar to $15. Strong sector view, Credit Suisse said. 2010 and 2011 EPS estimates raised to $0.87 and $1.25, respectively. Maintain Neutral rating.

Darden Restaurants

(DRI) - Get Report

target boosted at Oppenheimer to $57. Company is likely seeing higher sales, especially at Red Lobster.

Edwards Lifesciences

(EW) - Get Report

price target higher at Barclays to $80 from $75. Building out commercial infrastructure ahead of the potentially significant Sapien launch, Barclays said. Maintain Overweight rating.

Health Management Associates


price target boosted at Barclays by a dollar to $11. HMA has shown continued signs of progress with better-than-expected revenue growth, Barclays said. Maintain Overweight rating.

US Airways Group


price target raised at Barclays by a dollar to $15. Supply and demand balance in the industry will improve in the coming years, Barclays said. Maintain Equal Weight rating.

Novellus Systems


target, estimate boosted at Barclays to $43 from $35 on stronger growth, Credit Suisse said. 2011 and 2012 EPS estimates increased to $3.56 and $3.69, respectively. Maintain Outperform rating.

Occidental Petroleum

(OXY) - Get Report

target increased at Oppenheimer. OXY target was raised to $105, Oppenheimer said. Company recently boosted its dividend and should continue to generate steady cash flow.

Pioneer Natural

(PXD) - Get Report

target raised at Oppenheimer. Shares of PXD now seen reaching $96, according to Oppenheimer. Company can continue to outperform its peers, despite lower energy prices.



price target raised at Barclays. TSO price target increased to $20 from $16 after positive meeting with management, Barclays said. Maintain Equal Weight rating.

This article was written by a staff member of TheStreet.